Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00185757 · ClinicalTrials.gov registry record · Phase 1
Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00185757: Completed Phase 1 study, sponsored by Stanford University.
NCT00185757 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00185757, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a phase 1 dose escalation study evaluating the use of activated T-cells to treat relapsed malignancy (cancer) following allogeneic hematopoietic cell transplantation, without causing GvHD.
Interventions
- DRUG Cytokine Induced Killer Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2004-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00185757
The ClinicalTrials.gov registry entry for NCT00185757 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cytokine Induced Killer Cells is the first listed.
NCT00185757 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00185757 about?
NCT00185757 is a clinical study titled "Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation". This is a phase 1 dose escalation study evaluating the use of activated T-cells to treat relapsed malignancy (cancer) following allogeneic hematopoietic cell transplantation, without causing GvHD.
What is the current status of trial NCT00185757?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2004-06. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00185757?
The interventions under investigation include: Cytokine Induced Killer Cells (DRUG).
Who is sponsoring clinical trial NCT00185757?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.